Advertisement

Indian Journal of Surgery

, Volume 77, Supplement 2, pp 505–510 | Cite as

Gastrointestinal Stromal Tumours: Review of 150 Cases from a Single Centre

  • Myla Yacob
  • Samarasam Inian
  • Chandran B. Sudhakar
Original Article

Abstract

Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. They constitute a significant percentage ranging from 1–2 % of all the gastrointestinal neoplasms [11]. Knowledge on the molecular biology and behavior of these tumours is still not very clear. The clinicopathologial features are variable and surgical resection with chemotherapy is the main modality of treatment. We have retrospectively analyzed the clinicopathological features, treatment and prognosis of 150 patients managed in the Department of Surgery. Retrospective review of the records of 150 patients diagnosed with gastrointestinal stromal tumours and managed during the period January 2006 to December 2011. Clinicopathological features, immunohistochemistry, mitotic index, surgical resection adjuvant chemotherapy and survival analyzed. One hundred and fifty patients diagnosed with GIST and treated were reviewed. Ninety five of them were males (63.3 %). The tumour was most commonly seen during the fourth and fifth decades of life. Abdominal pain (52 %), intestinal bleeding (40 %) and abdominal mass (25 %) were the common clinical symptoms. Sixty percent of the tumours (90/150) were located in the stomach followed by small bowel (20 %) and duodenum (14.6 %). One hundred and thirty-five patients underwent excision of the tumour and five patients had multi organ resection of the adjacent organs like spleen, tail of the pancreas and kidney. Fifteen patients (10 %) received neoadjuvant Imatinib for down staging of the tumour prior to surgery. The tumour size ranged from 1 to 34 cm. One third of the tumours (42/150) belonged to the high-grade category. KIT protein (CD117) was positive in 90 %( 135/150), while CD34 was positive in 50 % (74/150) of tumours. Majority of the patients with high and intermediate-risk category received adjuvant Imatinib (65/77). Seventeen patients (11.3 %) developed recurrence of the tumour on follow-up and rest of the patients had stable disease. Eight of the 15 patients (53 %) who had advanced disease developed recurrence of the disease over 6 months to 1 year. Fifteen patients died on follow-up between 2 and 5 years. Gastrointestinal tumours are the most common non epithelial tumour of the GIT. GISTS are found to show a male preponderance and are common during the fourth and fifth decades. Abdominal pain and intestinal bleeding are the most common clinical presentation. Most of the tumours were located in the stomach. Surgical resection is the best modality of treatment for operable lesions. Tyrosine kinase receptor (KIT) inhibitor like imatinib is used for adjuvant treatment. Regular follow-up with ultra sonogram or computed tomogram helps in diagnosing disease recurrence.

Keyword

Gastrointestinal stromal tumours Surgical resection Chemotherapy Prognosis 

References

  1. 1.
    Perez EA, Ltd L, Franceschi D et al (2006) Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastro-intestinal stromal tumors. J Am Coll Surg 202:623–629PubMedCrossRefGoogle Scholar
  2. 2.
    Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22(18):3813–3825PubMedCrossRefGoogle Scholar
  3. 3.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRefGoogle Scholar
  4. 4.
    Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G et al (2000) KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791–795PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 8(2):S1–S41PubMedPubMedCentralGoogle Scholar
  6. 6.
    Vasantha A, Lakshmi RT, Chacko SK (2010) Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital. Indian journal of pathology and microbiology 53:628–633CrossRefGoogle Scholar
  7. 7.
    Miettinen M, Hala M, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum. A clinicopathological, immunohistochemical and molecular genetics study of 906 cases before imatinib with long term follow up. Am J Surg Pathol 30:477–489PubMedCrossRefGoogle Scholar
  8. 8.
    Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465PubMedCrossRefGoogle Scholar
  9. 9.
    Shah P, Gao F, Edmundowicz SA et al (2009) Predicting malignant potential of gastrointestinal stromal tumors using endoscopic ultrasound. Dig Dis Sci 54:1265–1269PubMedCrossRefGoogle Scholar
  10. 10.
    Deshaies I, Cherenfant J, Gusani NJ et al (2010) Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. Her Clin Risk Manag 6:453–8Google Scholar
  11. 11.
    Casali PG, Blay JY (2010) Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21(5):98–102CrossRefGoogle Scholar
  12. 12.
    Gold JS, DeMatteo RP (2006) Combined surgical and molecular therapy: the gastrointestinal stromal model. Ann Surg 244:176–184PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Antonescu CR (2006) Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Semin Diagn Pathol 23:63–69PubMedCrossRefGoogle Scholar
  14. 14.
    Parfitt J, Streutker C, Riddell R, Driman D (2006) Gastrointestinal stromal tumors: a contemporary review. Pathology - Research and Practice 202:837–847CrossRefGoogle Scholar
  15. 15.
    DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Joensuu H (2006) Gastrointestinal stromal tumor (GIST). Annals of Oncology 17(10):280–286CrossRefGoogle Scholar
  17. 17.
    Gastrointestinal Stromal Tumor Meta-Analysis Group (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 28:1247–1253CrossRefGoogle Scholar
  18. 18.
    Younus J, Verma S, Franek J et al (2010) Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol 17:4–10PubMedPubMedCentralGoogle Scholar
  19. 19.
    Blay JY, von Mehren M, Blackstein ME (2010) Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 116:5126–5137PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Yeh CN, Chen TW, Tseng JH et al (2010) Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 102:599–603PubMedCrossRefGoogle Scholar
  21. 21.
    Gastrointestinal stromal tumors PNAS (2008) 105:8387–8392Google Scholar
  22. 22.
    Ponsaing L, Hansen MB (2007) Therapeutic procedures fir submucosal tumors in the gastrointestinal tract. World J Gastroenterol 13(24):3316–3322PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Gupta P, Tewari M, Shulka H (2008) Gastrointestinal stromal tumor. Surg Oncol 17(2):129–138PubMedCrossRefGoogle Scholar
  24. 24.
    Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24(15):2325–2331PubMedCrossRefGoogle Scholar
  25. 25.
    Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121PubMedGoogle Scholar

Copyright information

© Association of Surgeons of India 2013

Authors and Affiliations

  • Myla Yacob
    • 1
  • Samarasam Inian
    • 1
  • Chandran B. Sudhakar
    • 1
  1. 1.Department of Surgery Unit 3Christian Medical College and HospitalVelloreIndia

Personalised recommendations